Cell-Free Nanotherapy Platform
Technologies and Programs 

aim to treat rare and refractory diseases with high unmet medical needs.

SBI-102

[SIRP-EV]

Membrane Protein

Discovery

IND-enabling

Clinical


Severe Alcoholic Hepatitis
/Acute Liver Failure (ALF)  ODD 


Rare

Efferocytosis of 

Inflammatory Dying Cells



Acute on Chronic 

Liver Failure (ACLF)

Rare

Efferocytosis of Inflammatory Dying Cells

/Phagocytosis of Pathological Fibroblasts



Idiopathic Pulmonary Fibrosis (IPF)


Rare

Phagocytosis of Pathological Fibroblasts



Pulmonary Arterial Hypertension (PAH)

Rare

Phagocytosis of Pathological Fibroblasts



Nonalcoholic Steatohepatitis (NASH)

Refractory

Phagocytosis of Pathological Fibroblasts



MSS Colorectal Cancer

Refractory

Phagocytosis of Cancer Cells



SBI-201 

[HIF1α-EV] 

Transcription Factor

Discovery

IND-enabling

Clinical


Peripheral Arterial Disease (PAD)

Undisclosed

Resolutive Immunity Activation


SBI-301 

ASO

Discovery

IND-enabling

Clinical


Undisclosed

Undisclosed

Undisclosed


SBI-302 

siRNA

Discovery

IND-enabling

Clinical


Undisclosed

Undisclosed

Undisclosed


Cell-Free Nanotherapy Platform
Technologies and Programs 

aim to treat rare and refractory diseases with high unmet medical needs. 



SIRP-NNP-MSC
SIRP-NNP-ASO
SIRP-NNP-siRNA
CBD-NNP-HIF1α
Ape-C-NNP-MSC
tBBB-NNP-Oligo
Program
MoA
Targeting CD47-overexpressing cells and reprogramming macrophages with MSC cargos
Targeting inflammatory lesions and efficiently delivering NLRP3 ASO intracellularly
Targeting tumor cells and efficiently delivering siRNA intracellularly
Enabling sustained release and enhancing resolutive immunity through HIF-1α delivery
Targeting pathological lesions and protecting cardiovascular function with apelin and MSC cargos
BBB penetration for beta-amyloid clearance
Indication(s)
Inflammatory / Fibrotic Diseases
Inflammatory Bowel Disease
Cold Tumor
Diabetic Ulcer
Pulmonary Arterial Hypertension
Alzheimer's Disease
Outer Cargo
SIRPα
SIRPα
SIRPα
Collagen binding domain
Apelin + CAR peptide
TFR1 binding moiety
Inner Cargo
Regenerative factor
NLRP3 ASO
siRNA (TBD)
HIF1α Transcription Factor
Regenerative factor
Oligonucleotide (TBD)

Program

Modality

Indication

Type

Mode of Action

Discovery

IND-enabling

Clinical

SBI-102

[SIRP-EV]

Membrane

Protein

Severe Alcoholic Hepatitis
/Acute Liver Failure (ALF)  ODD 

Rare

Efferocytosis of 

Inflammatory Dying Cells


Acute on Chronic 
Liver Failure (ACLF)

Rare

Efferocytosis of Inflammatory Dying Cells

/Phagocytosis of Pathological Fibroblasts


Idiopathic Pulmonary 
Fibrosis (IPF)

Rare

Phagocytosis of Pathological Fibroblasts


Pulmonary Arterial 
Hypertension (PAH)

Rare

Phagocytosis of Pathological Fibroblasts


Nonalcoholic Steatohepatitis
(NASH)

Refractory

Phagocytosis of Pathological Fibroblasts


MSS Colorectal Cancer

Refractory

Phagocytosis of Cancer Cells


SBI-201

[HIF1α-EV]

Transcription Factor

Peripheral Arterial
Disease (PAD)

Undisclosed

Resolutive Immunity Activation


SBI-301

ASO

Undisclosed

Undisclosed

Undisclosed


SBI-302

siRNA

Undisclosed

Undisclosed

Undisclosed